2 enrolling by invitation, 2 not yet recruiting, 1 unknown. 2 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Enrolling by invitation 1, Unknown 1 |
| Phase 2 | 1 | Enrolling by invitation 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Glucagon-Like Peptide-1 Receptor Agonists: new trials by email Literature Review of Glucagon-Like Peptide-1 Receptor Agonists trials Research Report on Glucagon-Like Peptide-1 Receptor Agonists
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms Semaglutide 1.0 mg, Semaglutide 0.5 mg - Glucagon-Like Peptide-1 Receptor Agonists, Type 2 Diabetes | Phase 4 | Not yet recruiting | Taipei Veterans General Hospital, Taiwan | 60 | 2025-10-01 | 2025-07-18 |
| Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying Ultrasound of gastric contents - Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists | Enrolling by invitation | Wael Saasouh, MD | 100 | 2025-09-01 | 2026-07-16 | |
| Role of Glucagon-like Peptide-1 Receptor Agonists in Menstrual Irregularities in Adolescent Females With Type 1 Diabetes Mellitus Dulaglutide - Menstrual Irregularities, Type1 Diabetes Mellitus | Phase 1 / Phase 2 | Enrolling by invitation | Ain Shams University | 50 | 2025-08-04 | 2026-06-05 |
| Impact of GLP-1 Receptor Agonists on Patients With IPMN GLP1 receptor agonist - IPMN, IPMN, Pancreatic | Not yet recruiting | Hôpital Fribourgeois | 30 | 2025-05-31 | 2025-06-11 | |
| HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects HDM1002 100 mg QD 12weeks, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks，Q 2W for titration - Glucagon-Like Peptide-1 Receptor Agonists | Phase 1 | Unknown | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 72 | 2024-07-28 | 2024-07-25 |
Diabetes Mellitus, Type 2 (1) · Intermittent Fasting (1) · Menstruation Disturbances (1) · Pancreatic Intraductal Neoplasms (1) · Respiratory Aspiration of Gastric Contents (1)
Digestive System Diseases (2) · Endocrine System Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Behavior (1) · Deglutition Disorders (1) · Diabetes Mellitus (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Esophageal Diseases (1) · Esophageal Motility Disorders (1) · Fasting (1) · Feeding Behavior (1) · Gastroesophageal Reflux (1) · Gastrointestinal Diseases (1)
dulaglutide (1) · semaglutide (1)
Ain Shams University (1) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1) · Hôpital Fribourgeois (1) · Taipei Veterans General Hospital, Taiwan (1) · Wael Saasouh, MD (1)
China (1) · Egypt (1) · Switzerland (1) · Taiwan (1) · United States (1)
Xiaoying Li (1)